

Docket Number: 037003-0307368

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of

NABIL HANNA, et al.

Group Art Unit: 1642

Application No.: 10/743,739

Examiner: M. Davis

Filed: December 24, 2003

Confirmation No.: 9111

For: SYNERGISTIC COMPOSITION AND METHODS FOR TREATING NEOPLASTIC OR
CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING HEMATOPOIESIS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application.

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

The fee pursuant to 37 CFR 1.17(i)(p).

Respectfully Submitted,

PILLSBURY WINTHROP SHAW PITTMAN LLP

/ thomas a cawley jr /

Thomas A. Cawley, Jr., Ph.D.

Registration Number 40944

Customer Number: 00909

Date: December 8, 2006
Telephone: (703) 770-7900
Facsimile: (703) 770-7901
P.O. Box 10500
McLean, VA 22102

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/743,739
				<i>Filing Date</i>	12/24/2003
				<i>First Named Inventor</i>	NABIL HANNA
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	M. Davis
(Use as many sheets as necessary)				<i>Attorney Docket Number</i>	037003-0307368
Sheet	1	of	1		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		L. BRAUN, "Regulation of growth and gene expression in human papillomavirus -transformed keratinocytes by transforming growth factor-beta: implications for the control of papillomavirus infection," Mol. Carcinog., Vol. 6 (No. 2), p. 100-111, (1992).		
		EA RORKE, "Transforming growth factor-beta 1 (TGF beta 1) enhances apoptosis in human papillomavirus type 16-immortalized human ectocervical epithelial cells," Exp. Cell Res., Vol. 216 (No. 1), p. 65-72, (Jan 1995).		
		J. JACOBBERGER, "Transforming growth factor beta regulation of epidermal growth factor receptor in ectocervical epithelial cells," Exp. Cell. Res. Vol. 220 (No. 2), p. 390-396, (Oct 1995).		
		M. OZBUN, "Transforming growth factor beta 1 induces differentiation in human papillomavirus-positive keratinocytes," J. Virol., Vol. 70 (No. 8), p. 5437-5436, (Aug 1996).		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.